This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
“However, around the time of the Human Genome Project, there was a ‘land grab’ for the new technologies as big pharmaceuticals tried to catch up paying high prices to access technology platforms in areas such as genomics and high throughput screening.” “Biotechnology has exploded across the industry. .
The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression. The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression.
Cardiac biomarkers can not only serve important roles in the diagnosis, management and prognosis of cardiac diseases, but they can also be significant tools in evaluating treatments in cardiovascular (CV) clinical trials. In CV clinical trials, cardiac biomarkers are most commonly included in efficacy and safety endpoints.
Preclinical data suggest VIR-7831 targets a highly conserved epitope of the spike protein, which may make it more difficult for resistance to develop. About the VIR-7831 ClinicalDevelopment Programme. The interim analysis included 291 patients in the treatment arm and 292 patients in the placebo arm.
New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinicaldevelopment programme. New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers. Join this event on Roche’s LinkedIn page here. Roche highlights featured at ESMO Virtual Congress 2020.
Roche’s Chief Medical Officer and Head of Global Product Development. Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. The EUA is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVID-19 in more than 5,500 hospitalised patients.
This blog highlights the top 10 biotech trends for 2025, showcasing cutting-edge technologies and approaches that promise to redefine patient care, accelerate drug development and expand our understanding of human biology. Related: Biotech IPOs in 2024: Navigating the New Wave of Innovation 1.
academic to industry) involved in developing CGTs, the guidance starts by summarizing some of the fundamentals of opening an IND. Even if an EOP2 meeting has occurred, it may help to have a focused clinical/statistical discussion of study results following Phase 3, as an EOP3 meeting.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content